Publication
Article
Pharmacy Times
PRODUCT news
Budeprion Hydrochloride Extended-release Tablets
Marketed by:
Teva Pharmaceuticals (North Wales, PA)
Compared to:
Wellbutrin XL (GlaxoSmithKline)
Indication:
May 30, 2008—Teva Pharmaceuticals announced theintroduction and availability of Budeprion XL (bupropionhydrochloride extended-release tablets USP [XL]),150 mg. The product is AB-rated and bioequivalent toWellbutrin XL tablets. Budeprion XL, an antidepressantof the aminoketone class, is indicated for the treatmentof major depressive disorder. A major depressiveepisode implies the presence of depressed mood orloss of interest or pleasure. With the addition of thisnew strength, Teva now offers the tablets in 150- and300-mg strengths, in bottle sizes of 30 and 500. Allpatients being treated with antidepressants for anyindication should be monitored and observed forclinical worsening, suicidality, and unusual behavior,especially during the initial few months of therapy or attimes of dose changes.
Dosage Form:
Tablets: 150 and 300 mg
For More Information:
888-TEVA USA (888-838-2872)
Cetirizine Hydrochloride Syrup, 1 mg/mL
Marketed by:
Perrigo Co (Allegan, MI)
Compared to:
Zyrtec Syrup (McNeil Consumer Healthcare)
Indication:
June 19, 2008—Perrigo Coannounced that it receivedFDA approval to manufacture and market CetirizineHydrochloride Syrup (Rx only), 1 mg/mL. The productis indicated for the relief of symptoms associatedwith seasonal allergic rhinitis, and it is comparable toMcNeil Consumer Healthcare's Zyrtec Syrup, 1 mg/mL.This product will add to Perrigo's already existing lineof Cetirizine tablets, Cetirizine D, and Cetirizine OTCsyrup.
Dosage Form:
Syrup: 1 mg/mL
For More Information:
Dronabinol
Marketed by:
Par Pharmaceutical Companies Inc (Woodcliff Lake, NJ)
Compared to:
Marinol (Solvay Pharmaceuticals)
Indication:
June 30, 2008—Par Pharmaceutical Companiesannounced that it received approval from the FDA forits Abbreviated New Drug Application for dronabinol,a generic version of Solvay Pharmaceuticals' Marinol,a CIII controlled substance. This product is approvedto treat nausea and vomiting associated with cancerchemotherapy in patients who have failed to respondadequately to conventional antiemetic treatments.Dronabinol is contraindicated in any patient who has ahistory of hypersensitivity to any cannabinoid, sesameoil, or any ingredients in dronabinol capsules. Warnpatients not to drive, operate machinery, or engage inhazardous activity until they establish that they can toleratedronabinol and perform such tasks.
Dosage Form:
Capsules: 2.5, 5, and 10 mg
For More Information:
Rifampin
Marketed by:
Lannett Co Inc (Philadelphia, PA)
Compared to:
Rifadin Capsules (sanofi-aventis US LLC)
Indication:
March 31, 2008—Lannett Co Inc,a manufacturerof generic pharmaceuticals,announced thatit received FDAapproval for its Abbreviated New Drug Applicationfor Rifampin capsules in 150- and 300-mg strengths.Rifampin is indicated in the treatment of all forms oftuberculosis and for the treatment of asymptomaticcarriers of Neisseria meningitidis to eliminate meningococcifrom the nasopharynx.
Dosage Form:
Capsules: 150 and 300 mg
For More Information:
